TABLE 1A.

Baseline alkaline phosphatase values for key phase 2 and 3 trials in PBC

Trial agent	Mean baseline ALP	Mean baseline ALP:ULN ratio
OCA phase 224	287±164	2.2
OCA phase 3 (“POISE”)16	326±196	2.5
OCA phase 3 confirmatory (“COBALT”)25	490±285	3.8
Bezafibrate phase 317	243±114	1.8
Elafibranor phase 3 (“ELATIVE”)21	322±151	3.1
Seladelpar phase 3 (“ENHANCE”)20	292±171	2.3
Budesonide phase 226	341±182	2.6

Abbreviation: ALP, alkaline phosphatase.